PMV PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Amortized Cost
PMV PHARMACEUTICALS, INC. (PMVP) had Debt Securities, Available-for-sale, Amortized Cost of $79.49 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-14
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $79.49M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $93.48M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $112.77M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $129.07M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $79.49M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $93.48M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $112.77M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $129.07M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $148.19M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $165.66M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $183.07M 10-K · filed 2026-03-06 |
| 2024-09-30 | $197.44M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $213.02M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $213.18M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $228.36M 10-K · filed 2025-03-03 |
| 2023-09-30 | $238.20M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $215.66M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $223.50M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $242.56M 10-K · filed 2024-02-29 |
| 2022-09-30 | $258.38M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $275.14M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $293.93M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $310.64M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |